Specialty Pharma Journal Specialty, Precision & Technology
NASHVILLE, Tenn. and TOKYO and MUNICH and BASKING RIDGE, N.J., Dec. 10, 2018 /PRNewswire/ — Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Sarah Cannon Research Institute announced today a strategic oncology development collaboration. This partnership brings together Daiichi Sankyo’s expertise in developing novel cancer agents with Sarah Cannon’s leadership …
Tag Archives: cancer
December, 2018
-
7 December
Myriad Study Demonstrates EndoPredict Can Guide Chemotherapy Decision for Women with Early-Stage Breast Cancer
SALT LAKE CITY, Dec. 07, 2018 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that academic researchers from the Technical University of Munich (TUM) presented the first prospective outcomes data on EndoPredict® at the San Antonio Breast Cancer Symposium in San Antonio, Texas. …
November, 2018
-
20 November
Boston Scientific Offers to Buy UK Medical Device Firm BTG for $4.2 Billion
MARLBOROUGH, Mass., Nov. 20, 2018 /PRNewswire/ — Boston Scientific (NYSE: BSX) today announced it has reached an agreement on the terms of a recommended offer to acquire BTG plc. (LSE: BTG), a company headquartered in the United Kingdom, which develops and commercializes products used in minimally-invasive procedures targeting cancer and vascular diseases, as well …
-
20 November
Genentech to Pay $100 Million to Immunocore to Co-Develop Investigational Drug Targeting Tumors Expressing MAGE-A4
(Oxford, UK and Conshohocken, US, 19 November 2018) Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company focused on delivering first-in-class biological therapies that have the potential to transform lives of people with serious diseases, today announces it has entered into a new partnership with Genentech, a member of …
-
16 November
Identification of LZTR1 Leads to Novel Insights into RAS-Driven Diseases
Mutations in RAS proteins initiate many of the most aggressive tumors, and the search for pharmacological inhibitors of these proteins has become a priority in the battle against cancer. Michail Steklov, Francesca Baietti, and colleagues from the Anna Sablina lab (VIB-KU Leuven Center for Cancer Biology) identified LZTR1 as an …
-
15 November
Boehringer Ingelheim and Epizyme Partner for Development of Novel Epigenetic Oncology Therapies
CAMBRIDGE, Mass. and INGELHEIM, Germany–(BUSINESS WIRE)–Boehringer Ingelheim and Epizyme, Inc. (Nasdaq: EPZM) today announced a new global collaboration focused on the research, development and commercialization of novel small molecule inhibitors directed toward two previously unaddressed epigenetic targets as potential therapies for people with cancer. Specifically, these targets are enzymes within …
-
9 November
Celldex Presents Promising Interim Data from Phase 1 Study of Differentiated CD40 Agonist CDX-1140
HAMPTON, N.J., Nov. 09, 2018 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented interim data today from the Phase 1 dose-escalation study of CDX-1140, a fully human agonist anti-CD40 antibody. CD40, expressed on dendritic cells and other antigen presenting cells, has long been an important target for immunotherapy, as it …
-
7 November
Lilly and NextCure Announce Collaboration to Discover and Develop Novel Immuno-Oncology Medicines
INDIANAPOLIS and BELTSVILLE, Md., Nov. 5, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and NextCure, Inc. today announced a multi-year collaboration focused on the discovery and development of immuno-oncology therapies. The collaboration seeks to discover novel cancer targets utilizing NextCure’s proprietary FIND-IO™ platform. Under the terms of the agreement, Lilly and NextCure will each receive options …
-
2 November
FDA Approves Coherus’ Udenyca, a Biosimilar to Neulasta
REDWOOD CITY, Calif., Nov. 02, 2018 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (NASDAQ: CHRS), today announced that the U.S. Food and Drug Administration (FDA) has approved UDENYCA™ (pegfilgrastim-cbqv), the first pegfilgrastim biosimilar approved by both the FDA and the European Commission (EC) for patients with cancer receiving myelosuppressive chemotherapy. UDENYCA™ …
-
1 November
Gilead and Tango Therapeutics Announce Strategic Collaboration to Develop Next-Generation Targeted Immuno-Oncology Therapies
FOSTER CITY, Calif. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) and Tango Therapeutics, Inc., a company focused on the discovery and development of novel cancer therapies, today announced a global strategic collaboration to discover, develop and commercialize a pipeline of innovative targeted immuno-oncology treatments for patients with cancer. Under …